Format

Send to

Choose Destination
Exp Neurol. 2014 Dec;262 Pt A:52-6. doi: 10.1016/j.expneurol.2014.02.015. Epub 2014 Feb 22.

Mode of action and clinical studies with fumarates in multiple sclerosis.

Author information

1
Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
2
Department of Neurology, St. Josef-Hospital, Ruhr-University, Bochum, Germany. Electronic address: ralf.gold@rub.de.

Abstract

Multiple sclerosis (MS) as a chronic neuro-inflammatory and neurodegenerative disease of the central nervous system is frequently associated with severe disability and impairment in quality of life. Early disease-modifying treatment options have mainly focused on inflammatory aspects of the disease. Recently, the neurodegenerative features have received more attention in experimental models, paraclinical assessments and the evaluation of drug effects. Fumaric acid esters (FAEs) as orally available immunomodulatory and neuroprotective compounds have thus advanced to a highly interesting MS treatment option. Here, we will review the pharmaceutical history of FAEs, their immunomodulatory and putative neuroprotective mechanisms of action and clinical trial data in relapsing MS.

KEYWORDS:

DMF; Dimethyl fumarate; Immunomodulation; Neuroprotection; RRMS

PMID:
24568735
DOI:
10.1016/j.expneurol.2014.02.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center